GLP1R and type 2 diabetes mellitus: Modern therapies for type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists, combine clinically important reductions in blood glucose levels with weight loss and a low risk of hypoglycaemia [12].